Haemonetics Corporation

Equities

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 21:00:02 24/05/2024 BST 5-day change 1st Jan Change
88.34 USD -0.34% Intraday chart for Haemonetics Corporation -7.72% +3.31%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes MT
Haemonetics Insider Sold Shares Worth $254,443, According to a Recent SEC Filing MT
Haemonetics Plans Notes Offering MT
Barrington Research Raises Price Target on Haemonetics to $107 From $105, Keeps Outperform Rating MT
Haemonetics Seeks Acquisitions CI
Transcript : Haemonetics Corporation, Q4 2024 Earnings Call, May 09, 2024
Haemonetics' Fiscal Q4 Adjusted Earnings, Revenue Rise MT
Haemonetics Corporation Reports Earnings Results for the Full Year Ended March 30, 2024 CI
Haemonetics Corporation Reports Earnings Results for the Fourth Quarter Ended March 30, 2024 CI
Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025 CI
Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge MT
Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge CI
Haemonetics Corporation completed the acquisition of Advanced Cooling Therapy, Inc. CI
Haemonetics to Acquire Attune Medical for $160 Million MT
Haemonetics Q3 Adjusted Earnings, Revenue Increase; Shares Rise MT
Transcript : Haemonetics Corporation, Q3 2024 Earnings Call, Feb 08, 2024
North American Morning Briefing : S&P 500 to Open -2- DJ
Haemonetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2023 CI
Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024 CI
Transcript : Haemonetics Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM
Haemonetics Completes $255 Million Acquisition of OpSens MT
OpSens Brief: NYSE's Haemonetics Completed Acquisition MT
Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) for approximately CAD 330 million. CI
OpSens Receives Final Order For Its Acquisition By NYSE's Haemonetics MT
OpSens Brief: Says Received Final Order For Its Acquisition By NYSE's Haemonetics MT
Chart Haemonetics Corporation
More charts
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Company’s Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
88.34 USD
Average target price
112.5 USD
Spread / Average Target
+27.35%
Consensus
  1. Stock Market
  2. Equities
  3. HAE Stock
  4. News Haemonetics Corporation
  5. Haemonetics Names New Chief Financial Officer; Incumbent Retiring